This conference series brings together senior thought leaders from across multiple disciplines to discuss strategies, technologies and capabilities that accelerate biopharmaceutical development. The theme of the AccBio 2023 is “Applying enduring lessons from the pandemic, including accelerated development of a broad range of vaccines and therapeutics”.
Session topics include:
Enduring Lessons Learned From the Pandemic
Accelerating Development Using Predictive Technologies
Fast to Patients: Beyond mAb to new Modalities
KEYNOTE SPEAKERS
Rachel Chikwamba, South African Council for Scientific and Industrial Research
Raymond Deshaies, Amgen
Kevin Eggan, BioMarin Pharmaceutical Inc.
Alison Moore, Allogene
CONFERENCE CHAIRS
Glen Bolton, Amgen
Ganesh Vedantham, BioMarin
ORGANIZING COMMITTEE
Dana Anderson, Denali Therapeutics
Hanne Bak, Regeneron
Katy Barglow, 4D Molecular Therapeutics
Tim Charlebois, University of Delaware
Charles Cooney, Massachusetts Institute ofTechnology
Rohini Deshpande, Amgen
Chetan Goudar, Amgen
Aine Hanly, Vir Biotechnology
Brendan Hughes, BMS
Brian Kelley, Vir Biotechnology
Kelvin Lee, University of Delaware
J. Christopher Love, Massachusetts Institute of Technology
Greg Naugle, GSK
Gregg Nyberg, Landmark Bio
Stefanie Pluschkell, In Scope Coaching and Consulting
Arup Roy, Eli Lilly
Cleo Salisburt, Genentech
Jeff Salm, Pfizer
Gene Schaefer, University of Delaware
Who should attend:
-VP- to CEO-level thought leaders from the biopharmaceutical development and manufacturing fields
-Senior-level researchers from industry, government, and academia
-R&D leaders
-Program managers and industry executives
-Associated professionals in the fields of bioengineering, biotechnology, and bioprocessing
Register by July 26 for best rates!
Conference organized by the Society for Biological Engineering